Final Approval In Glumetza Antitrust Deal Gives Attys $50M

A California federal judge granted final approval of three settlements resolving direct buyers' class claims that drugmakers plotted to delay the generic version of the blockbuster diabetes drug Glumetza, awarding $50 million...

Already a subscriber? Click here to view full article